Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-04-08FDA Approved: VABRINTY — Supplemental Application (URONOVA PHARMACEUTICALS, INC.)
FDA approved a supplemental application for VABRINTY (leuprolide acetate) filed by Uronova Pharmaceuticals. This action approves the supplem…
-
FDA label_change · 2011-04-08FDA Approved: VABRINTY — Supplemental Application (URONOVA PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for VABRINTY (leuprolide acetate) from URONOVA PHARMACEUTICALS, INC.
-
CLINICAL_TRIALS withdrawal · 2011-04-08Clinical Trial Update: Involvement of Endogenous Digitalis-like Compounds in Breast Cancer
Clinical trial NCT00310882 has been withdrawn; it investigated the involvement of endogenous digitalis-like compounds in breast cancer.
-
CLINICAL_TRIALS research · 2011-04-07Clinical Trial Update: Adjuvant Whole Breast Radiotherapy (RT) With Intensity Modulated Radiotherapy (IMRT) and a Simultaneous Integrated Boost Versus Conventional RT and a Sequential Boost [Phase 3]
A Phase 3 clinical trial comparing adjuvant whole-breast radiotherapy using IMRT with a simultaneous integrated boost against conventional r…
-
CLINICAL_TRIALS research · 2011-04-05Clinical Trial Update: Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating prophylactic irradiation of the contralateral breast in BRCA mutation carriers undergoing treatment for br…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-04-04Clinical Trial Update: Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer [Phase 2]
Phase 2 clinical trial comparing standard chemotherapy regimens with versus without ixabepilone (Ixempra) given before surgery in early-stag…
-
CLINICAL_TRIALS trial_result · 2011-04-04Clinical Trial Update: Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer [Phase 2]
Phase 2 study evaluating trastuzumab, ixabepilone, and carboplatin in HER2-positive metastatic breast cancer has completed with results post…
-
FDA approval · 2011-03-28FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application from Sandoz Inc. for Leuprolide acetate (ANDA 074728).
-
CLINICAL_TRIALS trial_result · 2011-03-28Clinical Trial Update: Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer [Phase 1]
Phase 1 trial evaluating trastuzumab with chemotherapy, followed by surgery and additional chemotherapy, in women with locally advanced brea…
-
CLINICAL_TRIALS trial_result · 2011-03-28Clinical Trial Update: Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer [Phase 1, Phase 2]
A clinical trial evaluating liposomal doxorubicin in combination with trastuzumab for women with advanced breast cancer has completed Phase …
-
FDA approval · 2011-03-25FDA Approved: EXEMESTANE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approval of a supplemental application for Exemestane by Mylan Pharmaceuticals Inc. is noted. Exemestane is a drug used in the treatment…
-
CLINICAL_TRIALS research · 2011-03-25Clinical Trial Update: Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma
The document discusses a clinical trial evaluating circulating tumor cells as a potential screening test for clinically undetectable breast …
-
CLINICAL_TRIALS trial_result · 2011-03-24Clinical Trial Update: Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors [Phase 2]
Phase 2 trial evaluating vaccine therapy in combination with interleukin-2 and sargramostim in patients with advanced tumors has completed.
-
CLINICAL_TRIALS trial_result · 2011-03-24Clinical Trial Update: Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating doxorubicin and paclitaxel for locally advanced breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2011-03-24Clinical Trial Update: Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer [Phase 2]
A Phase 2 trial evaluating bavituximab in combination with paclitaxel and carboplatin for breast cancer (Stage IV) has completed and reporte…
-
CLINICAL_TRIALS trial_result · 2011-03-24Clinical Trial Update: Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer [Phase 1, Phase 2]
This study evaluated tamoxifen citrate decision aids for women at increased risk of breast cancer in Phase 1 and Phase 2, and the trial has …
-
CLINICAL_TRIALS research · 2011-03-24Clinical Trial Update: Use of Stem Cells in Lymphedema Post Mastectomy [Phase 1, Phase 2]
Phase 1/2 trial evaluating stem cell therapy for lymphedema after mastectomy has completed.
-
CLINICAL_TRIALS research · 2011-03-24Clinical Trial Update: Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a multi-drug adjuvant regimen for HER2-positive breast cancer, combining bevacizumab and trastuzumab with …
-
CLINICAL_TRIALS research · 2011-03-23Clinical Trial Update: Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
A clinical trial update describing a study of breast cancer risk in women who are BRCA1 or BRCA2 mutation carriers. The current status of th…
-
FDA label_change · 2011-03-21FDA Approved: FARESTON — Supplemental Application (Kyowa Kirin, Inc.)
FDA approved a supplemental application for Fareston (toremifene citrate) submitted by Kyowa Kirin, Inc., resulting in a labeling update for…
-
FDA approval · 2011-03-17FDA Approved: ANASTROZOLE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Anastrozole from Accord Healthcare Inc., enabling a generic version of the breast cancer therapy…
-
CLINICAL_TRIALS trial_result · 2011-03-16Clinical Trial Update: Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery
The completed clinical study evaluated predictive genetic markers for toxicity in patients with breast cancer treated with hypofractionated …
-
CLINICAL_TRIALS trial_result · 2011-03-15Clinical Trial Update: Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer? [Phase 2]
This is a Phase 2 clinical trial update reporting the completion of a study evaluating whether community cancer support groups reduce physio…
-
CLINICAL_TRIALS trial_result · 2011-03-15Clinical Trial Update: A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer [Phase 2]
Phase 2 study of dasatinib in patients with advanced/metastatic breast cancer (triple-negative) completed; results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-03-14Clinical Trial Update: Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer [Phase 2]
Phase II trial evaluating the combination of oral vinorelbine and trastuzumab as first-line therapy for HER2-positive metastatic breast canc…